WO2013064714A8 - Fármacos inhibidores de p38 y aplicaciones - Google Patents

Fármacos inhibidores de p38 y aplicaciones Download PDF

Info

Publication number
WO2013064714A8
WO2013064714A8 PCT/ES2012/070762 ES2012070762W WO2013064714A8 WO 2013064714 A8 WO2013064714 A8 WO 2013064714A8 ES 2012070762 W ES2012070762 W ES 2012070762W WO 2013064714 A8 WO2013064714 A8 WO 2013064714A8
Authority
WO
WIPO (PCT)
Prior art keywords
inhibiting
drugs
mapk
activation
biological activity
Prior art date
Application number
PCT/ES2012/070762
Other languages
English (en)
French (fr)
Other versions
WO2013064714A1 (es
Inventor
Federico MAYOR MENÉNDEZ
Cristina Murga Montesinos
Pedro Manuel Campos Muelas
Jacoba Johana HEIJNEN
Anna Maria Agnes Antonius Kavelaars
Antonio MORREALE DE LEÓN
Rubén GIL REDONDO
Original Assignee
Universidad Autónoma de Madrid
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universidad Autónoma de Madrid filed Critical Universidad Autónoma de Madrid
Priority to EP12846045.8A priority Critical patent/EP2774613A4/en
Priority to JP2014539368A priority patent/JP2014532688A/ja
Priority to US14/355,545 priority patent/US9096554B2/en
Priority to BR112014010560A priority patent/BR112014010560A2/pt
Priority to CA2854349A priority patent/CA2854349A1/en
Priority to AU2012331016A priority patent/AU2012331016A1/en
Priority to KR1020147014457A priority patent/KR20140085580A/ko
Publication of WO2013064714A1 publication Critical patent/WO2013064714A1/es
Publication of WO2013064714A8 publication Critical patent/WO2013064714A8/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/12—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Se describen compuestos con estructura de benzooxadiazolil amina con capacidad para inhibir la activación o la actividad biológica de la proteín kinasa activada por mitógeno (MAPK) p38 y su empleo en el tratamiento de una enfermedad que puede ser aliviada mediante la inhibición de la activación o actividad biológica de dicha MAPK p38, por ejemplo, una enfermedad inflamatoria o una enfermedad que cursa con dolor.
PCT/ES2012/070762 2011-11-02 2012-10-31 Fármacos inhibidores de p38 y aplicaciones WO2013064714A1 (es)

Priority Applications (7)

Application Number Priority Date Filing Date Title
EP12846045.8A EP2774613A4 (en) 2011-11-02 2012-10-31 P38-INHIBITING PHARMACEUTICAL COMPOUNDS AND THEIR APPLICATIONS
JP2014539368A JP2014532688A (ja) 2011-11-02 2012-10-31 ｐ３８を阻害するための薬物およびそれらの用途
US14/355,545 US9096554B2 (en) 2011-11-02 2012-10-31 Drugs for inhibiting p38 and uses thereof
BR112014010560A BR112014010560A2 (pt) 2011-11-02 2012-10-31 drogas para inibir p38 e usos das mesmas
CA2854349A CA2854349A1 (en) 2011-11-02 2012-10-31 Drugs for inhibiting p38 and uses thereof
AU2012331016A AU2012331016A1 (en) 2011-11-02 2012-10-31 Drugs for inhibiting p38 and uses thereof
KR1020147014457A KR20140085580A (ko) 2011-11-02 2012-10-31 p38을 억제하기 위한 약물 및 이의 적용

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES201131754A ES2396764B1 (es) 2011-11-02 2011-11-02 FÁRMACOS INHIBIDORES DE p38 Y APLICACIONES.
ESP201131754 2011-11-02

Publications (2)

Publication Number Publication Date
WO2013064714A1 WO2013064714A1 (es) 2013-05-10
WO2013064714A8 true WO2013064714A8 (es) 2014-06-12

Family

ID=48191418

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/ES2012/070762 WO2013064714A1 (es) 2011-11-02 2012-10-31 Fármacos inhibidores de p38 y aplicaciones

Country Status (9)

Country Link
US (1) US9096554B2 (es)
EP (1) EP2774613A4 (es)
JP (1) JP2014532688A (es)
KR (1) KR20140085580A (es)
AU (1) AU2012331016A1 (es)
BR (1) BR112014010560A2 (es)
CA (1) CA2854349A1 (es)
ES (1) ES2396764B1 (es)
WO (1) WO2013064714A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2396764B1 (es) 2011-11-02 2013-12-19 Universidad Autónoma de Madrid FÁRMACOS INHIBIDORES DE p38 Y APLICACIONES.
WO2014078479A2 (en) 2012-11-14 2014-05-22 The Board Of Regents Of The University Of Texas System INHIBITION OF HIF-2α HETERODIMERIZATION WITH HIF1β (ARNT)
JP6473146B2 (ja) * 2013-10-11 2019-02-20 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ピロロトリアジンキナーゼ阻害剤
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69926800T2 (de) 1999-01-13 2006-05-18 Warner-Lambert Company Llc Benzoheterozyklen und ihre verwendung als mek inhibitoren
WO2001005390A2 (en) 1999-07-16 2001-01-25 Warner-Lambert Company Method for treating chronic pain using mek inhibitors
DE60310730T2 (de) 2002-07-09 2007-05-16 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische zusammensetzungen aus anticholinergica und p38 kinase hemmern zur behandlung von erkrankungen der atemwege
US20040110755A1 (en) 2002-08-13 2004-06-10 Boehringer Ingelheim Pharmaceuticals, Inc. Combination therapy with p38 MAP kinase inhibitors and their pharmaceutical compositions
WO2004021988A2 (en) 2002-09-05 2004-03-18 Scios Inc. Treatment of pain by inhibition of p38 map kinase
US20080039461A1 (en) 2002-09-05 2008-02-14 Protter Andrew A Treatment of pain by inhibition of p38 map kinase
WO2005032551A1 (en) 2003-09-30 2005-04-14 Scios Inc. TREATMENT OF CARDIOVASCULAR DISEASE WITH INHIBITORS OF p38 KINASE
JP2008503591A (ja) * 2004-06-22 2008-02-07 ライジェル ファーマシューティカルズ， インコーポレイテッド ユビキチンリガーゼ阻害剤
EP1885181A2 (en) 2005-05-23 2008-02-13 Smithkline Beecham Corporation Inhibition of p38 mark for treatment of obesity
WO2008124838A1 (en) 2007-04-10 2008-10-16 University Of Maryland, Baltimore Compounds that inhibit human dna ligases and methods of treating cancer
GB0713311D0 (en) 2007-07-10 2007-08-22 Nene Group Plc Pallet racking shield
DE102007060008A1 (de) 2007-12-13 2009-06-18 Technolas Gmbh Ophthalmologische Systeme Bestimmung und Überwachumg von Laserenergie
WO2010083404A2 (en) 2009-01-16 2010-07-22 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Linked myc-max small molecule inhibitors
US20120122896A1 (en) * 2009-05-08 2012-05-17 Pike Pharma Gmbh 2,1,3-benzoxadiazol derivatives for the inhibition of influenza a and b virus and respiratory syncytial virus replication
ES2396764B1 (es) 2011-11-02 2013-12-19 Universidad Autónoma de Madrid FÁRMACOS INHIBIDORES DE p38 Y APLICACIONES.

Also Published As

Publication number Publication date
JP2014532688A (ja) 2014-12-08
ES2396764B1 (es) 2013-12-19
WO2013064714A1 (es) 2013-05-10
US9096554B2 (en) 2015-08-04
CA2854349A1 (en) 2013-05-10
US20140296308A1 (en) 2014-10-02
ES2396764A1 (es) 2013-06-19
AU2012331016A1 (en) 2014-06-26
EP2774613A4 (en) 2015-04-22
EP2774613A1 (en) 2014-09-10
KR20140085580A (ko) 2014-07-07
BR112014010560A2 (pt) 2017-04-25

Similar Documents

Publication Publication Date Title
CL2014002757A1 (es) Compuestos derivados de benzamida para inhibir la actividad de abl1, abl2 y bcr-abl1, composicion farmaceutica; y uso en el tratamiento del cancer.
WO2013012915A8 (en) Heterocyclic compounds and uses thereof
EP3357921A3 (en) Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
CL2012003722A1 (es) Compuestos derivados del acido naf-2-ilacetico; composicion farmaceutica; y uso para el tratamiento del sida.
EP3060251A4 (en) Treatment using bruton's tyrosine kinase inhibitors and immunotherapy
MX2021007268A (es) Formas solidas de acido {[5-(3-clorofenil)-3-hidroxipiridin-2-carb onil]amino}acetico, composiciones, y usos de las mismas.
DOP2014000062A (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
JOP20120246B1 (ar) مركبات و تركيبات كمثبطات كيناز c-Kit
CL2013003372A1 (es) Compuestos derivados de espiro-[1,3]-oxacinas y espiro-[1,4]-oxacepinas, inhibidores de bace1 y/o bace2; composicion farmaceutica; procedimiento para prepararlos; y su uso en el tratamiento y/o la profilaxis de la enfermedad de alzheimer y diabetes.
CL2013003051A1 (es) Compuestos derivados de pirazolo (4.3-d) pirimidinas, inhibidores de quinasa; composicion farmaceutica; y uso para el tratamiento de enfermedades y trastornos del aparato respiratorio
TN2014000068A1 (en) Compounds and compositions as c-kit kinase inhibitors
CL2014000849A1 (es) Compuestos derivados de benzilindazoles sustituido, inhibidores de la quinasa bub1; procedimiento de fabricacion; composicion farmaceutica; combinacion farmaceutica; y su uso en el tratamiento de enfermedades hiperproliferativas.
MX2014002486A (es) Compuestos y composiciones como inhibidores de cinasa pdgfr.
PH12015500114A1 (en) HUMAN ANTIBODIES TO GFRa3 AND METHODS OF USE THEREOF
EP2851429A4 (en) PROTEIN AND PROTEIN CONJUGATES FOR THE TREATMENT OF DIABETES AND APPLICATIONS THEREOF
MX2019003619A (es) Formulaciones de bromocriptina.
CL2014000007A1 (es) Compuestos derivados de oxazol y tiazol, inhibidores selectivos de proteinas quinasas; composicion farmaceutica; combinacion farmaceutica; su uso en el tratamiento de enfermedades tales como mastocitosis, neoplasia hematologica, trastorno mieloproliferativo, enfermedad autoinmune, enfermedad inflamatoria, alergias o enfermedad neurologica.
WO2012100043A3 (en) Controlled release oral pharmaceutical dosage forms comprising mgbg
EP2608786A4 (en) METHODS OF TREATING ALCOHOLIC INTOXICATION, DISORDERS ASSOCIATED WITH ALCOHOL CONSUMPTION AND ALCOHOL ABUSE USING DIHYDROMYRICETINE ADMINISTRATION
WO2013064714A8 (es) Fármacos inhibidores de p38 y aplicaciones
AU2012280776B2 (en) Compounds and pharmaceutical combinations for the treatment of neurodegenerative and ischemic brain diseases
CL2015001681A1 (es) Unidad solida con alto contenido en fexofenadina; procedimiento de preparacion; y uso de la misma como antihistaminico, broncodilatador y/o para el tratamiento de alergias y/o urticarias.
WO2014193800A3 (en) Aptamers for the treatment of sickle cell disease
WO2012149335A3 (en) Small molecule inhibitors of rgs proteins
UA112488C2 (uk) Три(гетеро)арилпіразоли і їх застосування

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12846045

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 14355545

Country of ref document: US

ENP Entry into the national phase in:

Ref document number: 2014539368

Country of ref document: JP

Kind code of ref document: A

Ref document number: 2854349

Country of ref document: CA

NENP Non-entry into the national phase in:

Ref country code: DE

ENP Entry into the national phase in:

Ref document number: 20147014457

Country of ref document: KR

Kind code of ref document: A

REEP Request for entry into the european phase

Ref document number: 2012846045

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2012846045

Country of ref document: EP

ENP Entry into the national phase in:

Ref document number: 2012331016

Country of ref document: AU

Date of ref document: 20121031

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112014010560

Country of ref document: BR

ENP Entry into the national phase in:

Ref document number: 112014010560

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20140430